AU2002355929A1 - Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same - Google Patents
Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing sameInfo
- Publication number
- AU2002355929A1 AU2002355929A1 AU2002355929A AU2002355929A AU2002355929A1 AU 2002355929 A1 AU2002355929 A1 AU 2002355929A1 AU 2002355929 A AU2002355929 A AU 2002355929A AU 2002355929 A AU2002355929 A AU 2002355929A AU 2002355929 A1 AU2002355929 A1 AU 2002355929A1
- Authority
- AU
- Australia
- Prior art keywords
- crystallized
- binding domain
- ligand binding
- screening methods
- receptor ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003676 Glucocorticoid Receptors Human genes 0.000 title 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 title 1
- 108020001756 ligand binding domains Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30590201P | 2001-07-17 | 2001-07-17 | |
| US60/305,902 | 2001-07-17 | ||
| PCT/US2002/022648 WO2003015692A2 (en) | 2001-07-17 | 2002-07-17 | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002355929A1 true AU2002355929A1 (en) | 2003-03-03 |
Family
ID=23182861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002355929A Abandoned AU2002355929A1 (en) | 2001-07-17 | 2002-07-17 | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US7238778B2 (en) |
| AU (1) | AU2002355929A1 (en) |
| WO (1) | WO2003015692A2 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6434489B1 (en) * | 2000-04-03 | 2002-08-13 | Schering Corporation | Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same |
| GB0209507D0 (en) * | 2002-04-25 | 2002-06-05 | Karobio Ab | Nuclear receptor structure |
| EP1375517A1 (en) * | 2002-06-21 | 2004-01-02 | Smithkline Beecham Corporation | Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same |
| ATE456100T1 (en) * | 2002-07-18 | 2010-02-15 | Bristol Myers Squibb Co | COMPOSITIONS AND METHODS RELATED TO THE NUCLEAR HORMONE RECEPTOR SITE II |
| JP2006265173A (en) * | 2005-03-24 | 2006-10-05 | Sumitomo Chemical Co Ltd | Crystal containing complex of glucocorticoid receptor ligand binding domain and ligand |
| WO2006117592A1 (en) * | 2005-04-29 | 2006-11-09 | Inserm | Methods of modulating nuclear receptors |
| JP2007008897A (en) * | 2005-07-04 | 2007-01-18 | Sumitomo Chemical Co Ltd | Crystal containing complex of glucocorticoid receptor ligand binding domain and ligand |
| US7910565B2 (en) | 2006-09-01 | 2011-03-22 | Wisconsin Alumni Research Foundation | Prostate cancer vaccine |
| US20120040938A1 (en) * | 2009-03-04 | 2012-02-16 | Shriners Hospital For Children | Glucocorticoid receptor alleles and uses thereof |
| US20120095055A1 (en) * | 2009-06-02 | 2012-04-19 | Merck Sharp & Dohme, Corp. | HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
| WO2011031574A1 (en) * | 2009-09-08 | 2011-03-17 | Merck Sharp & Dohme Corp. | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
| EP2609097A4 (en) * | 2010-08-27 | 2014-04-16 | Corcept Therapeutics Inc | Pyridyl-amine fused azadecalin modulators |
| WO2012031034A2 (en) | 2010-08-31 | 2012-03-08 | Lawrence Ganeshalingam | Method and systems for processing polymeric sequence data and related information |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| EP2864896A4 (en) | 2012-06-22 | 2016-07-20 | Dan Maltbie | SYSTEM AND METHOD FOR SECURE HIGH-SPEED TRANSFER OF VERY LARGE FILES |
| PT3848027T (en) | 2013-11-25 | 2023-05-11 | Corcept Therapeutics Inc | Octahydro fused azadecalin glucocorticoid receptor modulators |
| FI3600282T3 (en) | 2017-03-31 | 2025-11-07 | Corcept Therapeutics Inc | Glucocorticoid receptor modulators for the treatment of cervical cancer |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| PT3897589T (en) | 2018-12-19 | 2026-01-21 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| EP3927345A4 (en) | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | THERAPEUTIC USE OF RELACORILANT, A HETEROARYL KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATOR |
| IL291775A (en) | 2019-12-11 | 2022-06-01 | Corcept Therapeutics Inc | Methods of treating antipsychotic-induced weight gain with miricorilant |
| CN112553231A (en) * | 2020-12-25 | 2021-03-26 | 华南农业大学 | Recombinant human heat shock protein HSP90-His and expression and purification method thereof |
| CN112695052A (en) * | 2020-12-25 | 2021-04-23 | 华南农业大学 | Recombinant human glucocorticoid receptor GR alpha-His protein and expression and purification method thereof |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US20240400642A1 (en) * | 2022-06-27 | 2024-12-05 | Etern Therapeutics Inc. | Compositions and methods for modulating molecules |
| EP4598513A1 (en) | 2022-10-06 | 2025-08-13 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| AU2023367284A1 (en) | 2022-10-28 | 2025-05-29 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532167A (en) * | 1994-01-07 | 1996-07-02 | Beth Israel Hospital | Substrate specificity of protein kinases |
| FR2745008A1 (en) * | 1996-02-20 | 1997-08-22 | Ass Pour Le Dev De La Rech En | MODIFIED NUCLEAR GLUCOCORTICOID RECEPTOR, DNA FRAGMENTS ENCODING SAID RECEPTOR, AND METHODS IN WHICH THEY ARE USED |
| WO2000052050A2 (en) * | 1999-03-01 | 2000-09-08 | Karo Bio Ab | Homology models of the glucocorticoid receptor |
-
2002
- 2002-07-17 WO PCT/US2002/022648 patent/WO2003015692A2/en not_active Ceased
- 2002-07-17 US US10/484,061 patent/US7238778B2/en not_active Expired - Fee Related
- 2002-07-17 AU AU2002355929A patent/AU2002355929A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003015692A2 (en) | 2003-02-27 |
| US7238778B2 (en) | 2007-07-03 |
| US20050181362A1 (en) | 2005-08-18 |
| WO2003015692A3 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002355929A1 (en) | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same | |
| AUPR688101A0 (en) | Protein domains and their ligands | |
| AU2003285540A1 (en) | Antibody for the thyrotropin receptor and uses thereof | |
| AU2001239921A1 (en) | Antibody inhibiting the binding between GP120 and DC-SIGN and screening methods | |
| AU2001253020A1 (en) | Screening markers and methods for neurodegenerative disorders | |
| AU7433900A (en) | Screening methods | |
| AU2003298654A1 (en) | Structure of the farnesoid x receptor ligand binding domain and methods of use therefor | |
| AU1178100A (en) | Novel g protein-coupled receptor protein, its dna and ligand thereof | |
| AUPR959201A0 (en) | Screening panel securing system | |
| AU7904500A (en) | Method for the screening of alpha2delta-1 subunit binding ligands | |
| AU2002365111A1 (en) | Methods for identifying and using marr family polypeptide binding compounds | |
| AU6913100A (en) | Notch receptor ligands and uses thereof | |
| AU5671699A (en) | Grp receptor ligands | |
| AU4432901A (en) | Alpha 7 nicotinic receptor screening assays | |
| AU7902398A (en) | Assay methods and compositions useful for measuring receptor ligand binding | |
| AU2003221533A1 (en) | Ligands for g protein coupled receptor gpr7 and uses thereof | |
| AUPR869701A0 (en) | Screening panel securing system | |
| AU2002219218A1 (en) | Method for screening for progesterone receptor isoform-specific ligands | |
| AU2002332696A1 (en) | Solid support dirhodium catalyst compositions and methods for making and using same | |
| AU2002245372A1 (en) | Crystallized hnf4 gamma ligand binding domain polypeptide and screening methods employing same | |
| AU2002251874A1 (en) | Crystallized ppar$g(a) ligand binding domain polypeptide and screening methods employing same | |
| AU2003273152A1 (en) | Receptor and screening methods | |
| AU2002257287A1 (en) | Crystallized human xenobiotic nuclear receptor pxr/sxr ligand binding domain polypeptide and screening methods employing same | |
| AU2003226764A1 (en) | Novel glucocorticoid receptor ligands | |
| AU3678000A (en) | Method for screening g protein-coupled receptor ligand and method for expressioncloning g protein-coupled receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |